Market Performance - The Hong Kong stock market showed mixed performance with the Hang Seng Index up by 0.06% closing at 26,765.52 points, while the Tech Index fell by 1.24% to 5,725.99 points, and the National Enterprises Index decreased by 0.15% to 9,147.21 points [1][2]. Sector Performance - Traditional cyclical stocks such as oil, coal, and non-ferrous metals performed strongly, indicating a shift in market focus towards value assets. In contrast, previously popular sectors like commercial aerospace and brain-computer interface technologies experienced a pullback [2][11]. Oil Sector - Oil stocks saw significant gains, with China National Offshore Oil Corporation (CNOOC) rising by 4.01%, China Petroleum & Chemical Corporation (Sinopec) increasing by 3.68%, and China Oilfield Services Limited up by 3.23%. This strength is attributed to a recent extreme cold wave in North America, which caused a 63% spike in U.S. natural gas prices from January 20 to 22, subsequently boosting prices of light hydrocarbons and supporting domestic petrochemical prices [4][5]. Coal Sector - Coal stocks also showed robust performance, with Mongolian Energy up by 5.80%, China Shenhua Energy rising by 4.42%, and China Qinfa up by 3.74%. The increase in coal prices is linked to heightened demand due to cold weather, with daily coal output from the Bohai Rim ports averaging 1.682 million tons, a week-on-week increase of 14.2 tons or 9.19% [6][7]. Non-Ferrous Metals Sector - Non-ferrous metal stocks were active, with Rusal rising by 12.31%, China Nonferrous Mining increasing by 9.87%, and Chifeng Jilong Gold Mining up by 7.44%. Citigroup's report indicates a structural bull market in aluminum, predicting a 61,000-ton structural deficit by early 2026 and raising the price target for aluminum from $2,950 to $3,400 per ton [8][9]. Gold Market - Morgan Stanley's research indicates that gold prices have surpassed their forecast of $4,750 per ounce for the second half of the year, with expectations of further increases due to geopolitical risks, central bank purchases, and ETF inflows. A bullish scenario suggests a target price of $5,700 per ounce for the second half [10]. Weakness in Tech Sectors - Commercial aerospace stocks faced collective declines, with Asia Pacific Satellite down by 11.53%, Goldwind Technology down by 7.14%, and JunDa Co. down by 6.56%. This adjustment is attributed to short-term profit-taking pressures [11]. Brain-computer interface stocks also showed weakness, with Nanjing Panda Electronics down by 6.15% and Brainstorming Technology down by 5.35%, partly due to a recent share placement announcement [13][14]. Individual Stock Movements - Zhizhuo (02513.HK) surged by 13.02% following a significant increase in subscription service users after the launch of its flagship model GLM-4.7, indicating strong market interest in its AI capabilities [15]. Lao Pu Gold (06181.HK) rose by 7.80% due to increased customer traffic during a promotional event, with expectations of substantial revenue growth during the upcoming Spring Festival [16].

脑动极光-B(6681.HK)盘初一度跳水跌12%至5.6港元，截至目前成交额放大至6.7亿港元。消息面上，公 司宣布以先旧后新方式配售9200万股股份，占扩大后股本约6.77%；每股配股价5.6港元，较昨日收市价 6.37港元折让约12.09%；集资5.15亿港元。 公司称，所得款项净额预期约为5.01亿港元，当中，约50%将用于为研发计划拨付资金，约30%将用于 国内及国际市场开发，约10%将用于战略投资及收购，及约10%将作一般公司用途的营运资金。 ...

Core Viewpoint - The company, Brainstorm Cell Therapeutics (脑动极光-B), experienced a significant decline in stock price following the announcement of a share placement, indicating market reaction to the capital raising strategy [1] Group 1: Stock Performance - The stock opened down over 6%, currently trading at 5.97 HKD, reflecting a drop of 6.28% [1] - The trading volume reached 519 million HKD, indicating active market participation [1] Group 2: Share Placement Details - The company plans to place 92 million shares, representing approximately 6.77% of the enlarged share capital [1] - The placement price is set at 5.6 HKD per share, which is about 12.09% lower than the closing price of 6.37 HKD on January 22 [1] - The total capital raised is expected to be 515 million HKD, with a net amount of approximately 501 million HKD after expenses [1] Group 3: Use of Proceeds - Approximately 50% of the net proceeds will be allocated to research and development [1] - About 30% will be used for domestic and international market development [1] - Approximately 10% is earmarked for strategic investments and acquisitions, with another 10% designated for general corporate operational funds [1]

消息面上，脑动极光宣布，拟以先旧后新方式配售9200万股股份，占扩大后股本约6.77%；每股配股价 5.6港元，较1月22日收市价6.37港元折让约12.09%；集资5.15亿港元。所得款项净额预期约为5.01亿港 元，当中，约50%将用于为研发计划拨付资金，约30%将用于国内及国际市场开发，约10%将用于战略 投资及收购，及约10%将作一般公司用途的营运资金。 智通财经APP获悉，脑动极光-B(06681)低开逾6%，截至发稿，跌6.28%，报5.97港元，成交额5.19亿港 元。 ...

Group 1 - The company, Brainstorm Cell Therapeutics Inc. (6681.HK), plans to issue 92 million shares through a placement, representing approximately 6.77% of the enlarged share capital [1] - The placement price is set at HKD 5.6 per share, which is a discount of about 12.09% compared to the closing price of HKD 6.37 from the previous day [1] - The total funds raised are expected to be HKD 515 million, with a net amount of approximately HKD 501 million after expenses [1] Group 2 - Approximately 50% of the net proceeds will be allocated to research and development initiatives [1] - About 30% of the funds will be used for domestic and international market development [1] - The remaining 20% will be split between strategic investments and acquisitions (10%) and general corporate operational expenses (10%) [1]

Group 1 - The company, Brainstorm Aurora-B (06681.HK), has entered into a placement and subscription agreement to issue 92 million shares at a price of HKD 5.6 per share, which represents a discount of approximately 12.09% compared to the last closing price of HKD 6.37 [1] - The placement shares account for about 7.27% of the company's existing issued share capital as of the announcement date [1] - The seller, ZTan Limited, is wholly owned by the company's executive director and chairman, Tan Zheng, who, along with his concert parties, holds a combined 40.95% stake in the company [1] Group 2 - The estimated total proceeds from the subscription are approximately HKD 515.2 million, with a net amount of about HKD 500.7 million expected [2] - The net proceeds are intended to be allocated as follows: approximately 50% for funding research and development programs, about 30% for domestic and international market development, and around 10% for general working capital purposes [2]

Group 1 - The company, Brainstorm Aurora-B (06681), has entered into a placement and subscription agreement, with a share placement price set at HKD 5.6 per share, representing a discount of approximately 12.09% from the last closing price of HKD 6.37 [1] - The placement shares will account for about 7.27% of the company's existing issued share capital as of the announcement date, and approximately 6.77% after the completion of the subscription [1] Group 2 - The total estimated proceeds from the subscription are approximately HKD 515 million, with a net amount expected to be around HKD 501 million after deducting all related costs and expenses [2] - The company plans to allocate approximately 50% of the net proceeds for research and development programs, including the development of non-invasive brain-computer interface systems and consumer-oriented digital health platforms, expected to be fully utilized by September 30, 2027 [2] - About 30% of the net proceeds will be used for domestic and international market development, including costs related to establishing national branches and supporting academic conferences, expected to be fully utilized by June 30, 2027 [2] - Approximately 10% of the net proceeds will be allocated for strategic investments and acquisitions within the digital health ecosystem, expected to be fully utilized by June 30, 2027 [2] - The remaining 10% will be used to supplement the company's general working capital, expected to be fully utilized by December 31, 2026 [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券的邀請或要約。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 根據一般授權配售現有股份及先舊後新認購新股份 獨家整體協調人、配售代理及資本市場中介機構 董事會欣然宣佈，於2026年1月23日（交易時段前），本公司已訂立配售及認購 協議，配售及認購協議項下擬進行交易之所得款項總額合共估計約為515.20百 萬港元。 根據一般授權配售現有股份及先舊後新認購新股份 董事會欣然宣佈，於2026年1月23日（交易時段前），本公司、賣方及配售代理 訂立配售及認購協議，據此，(i)賣方已同意出售，而配售代理已同意作為賣方 之代理，盡力促使不少於六(6)名承配人按配售價每股配售股份5.6港元購買配售 股份，及(ii)賣方已有條件同意認購，而本公司已 ...

Group 1 - The core viewpoint of the article highlights that Brainstorm Cell Therapeutics (脑动极光-B, 06681) has seen significant stock activity, with shareholders depositing shares into Guotai Junan (Hong Kong), resulting in a market value of HKD 2.729 billion, accounting for 33.31% of the total [1] Group 2 - For the six months ending June 30, 2025, Brainstorm Cell Therapeutics reported revenue of HKD 100 million, representing a year-on-year increase of 92.82% [1] - The adjusted net loss for the company was HKD 88.022 million, which is an increase of 11.64% compared to the previous year [1] - The loss attributable to the company's owners was HKD 126 million, reflecting a year-on-year increase of 10.53%, with a loss per share of HKD 0.11 [1]

Group 1 - The core viewpoint of the article highlights that Brainstorm Cell Therapeutics Inc. (脑动极光-B) has deposited shares worth HKD 2.729 billion into Guotai Junan (Hong Kong), representing 33.31% of the total [1] - For the six months ending June 30, 2025, the company reported revenue of HKD 100 million, reflecting a year-on-year increase of 92.82% [1] - The adjusted net loss for the company was HKD 88.022 million, which is an increase of 11.64% compared to the previous year [1] - The loss attributable to the company's owners was HKD 126 million, marking a year-on-year increase of 10.53% [1] - The loss per share was reported at HKD 0.11 [1]